The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.
 
Faisal Fa'ak
No Relationships to Disclose
 
Nicolas Coudray
No Relationships to Disclose
 
George Jour
Stock and Other Ownership Interests - Celldex
Honoraria - Bristol-Myers Squibb; Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb
 
Clara Goldberg
No Relationships to Disclose
 
Paul Johannet
No Relationships to Disclose
 
Alexander Chan Chi Huang
Consulting or Advisory Role - Immunai
Research Funding - Bristol-Myers Squibb
 
Tara Mitchell
Consulting or Advisory Role - Bristol-Myers Squibb; GigaGen; Instil Bio; Merck; OncoSec
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)
 
Xiaowei Xu
Stock and Other Ownership Interests - CureBiotech; Exio Bioscience
Research Funding - Incyte
Patents, Royalties, Other Intellectual Property - Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
 
Aristotelis Tsirigos
Stock and Other Ownership Interests - Imagenomix; Intelligencia
Consulting or Advisory Role - Intelligencia
Research Funding - Roche
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; Evaxion Biotech; Instil Bio; NexImmune; OncoC4
Honoraria - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Ultimovacs; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Protean Biodiagnostics; Roche; Sellas Life Sciences; Ultimovacs; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Novartis; Roche
 
Iman Osman
Employment - Dracen (I)
Leadership - Dracen (I); Dracen (I)